The study emphasizes the need for further research to understand the comprehensive immunological response, considering factors like cellular immunity and potential confounding variables, to assess the vaccine's long-term efficacy in preventing COVID-19 in this population.Kleebayoon,...
22,23. This effect occurs to a similar extent in patients with cancer65,66. However, data correlating vaccine-induced specific T cells with clinical efficacy against COVID-19 remain limited. In one large UK keyworker cohort, T cell response was associated with protection from...
Xing says the antibody response to the Pfizer boost seems to be even stronger than the one most people generate after receiving two doses of the Oxford–AstraZeneca vaccine, according to earlier trial data. But it is not clear how those responses compare with those seen in people who receive...
BEIJING, June 16 (Xinhua) -- A China-developed mRNA COVID-19 vaccine as a third booster dose has been shown in human trials to be safe and able to induce an immune response against the Omicron variant. AWcorna, previously known as ARCoV, which encodes the receptor-binding domain of SARS...
An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today inThe New England ...
The strong response to one dose of the vaccine among those previously infected regardless of the duration between infection and vaccination is good news. However, the researchers emphasize that their findings should be confirmed in a larger cohort before reaching definitive c...
Scientists are using powerful genomics technologies to explore this and other major questions around the host immune response. Their discoveries will help inform the selection of therapies for clinical trials, vaccine development, and defining high-risk groups. ...
Sinovac Biotech reported that preliminary results from Phase I and II trials of its Covid-19 vaccine, CoronaVac, demonstrated it to be safe.
Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those previously infected with SARS-CoV-2 is still not completely understood.
Figure 3 Mechanism of NALT immune response after nasal vaccination NALT能够同时产生细胞、体液和黏膜三重免疫应答,而其他黏膜组织(如,口腔黏膜和阴道黏膜)并不具有这一特性。由于鼻黏膜给药独特的免疫优势,使得鼻腔免疫疫苗成为当前研究的热点。细胞免疫...